Pharmaceutical giant Pfizer Inc. has shared news of the European Commission approving the marketing of Emblaveo, aimed at treating adult patients affected by serious infectious diseases.
The approval covers the use of Emblaveo for complex intra-abdominal infections, hospital-obtained pneumonia, and intricate urinary tract infections, including pyelonephritis. The green light was given based on the results derived from the Phase 3 programs, incorporating the REVISIT and ASSEMBLE studies, which were shared earlier.
Pfizer also stated that Emblaveo is recommended for the treatment of infections caused by aerobic Gram-negative organisms in adults who have limited treatment options.
The authorization for marketing Emblaveo is recognized across all 27 member states of the European Union as well as in Iceland, Liechtenstein, and Norway.
